Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Inclusion Criteria:
Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Miami, Florida 33136-1002, United States
954-265-6549
New York, New York 10065-6007, United States
New York, New York 10065-6007, United States
Victoria, 3000, Australia
Aichi-Ken, 4600001, Japan
Cho-ku, 104-0045, Japan
Miyagi-Ken, 9808574, Japan
941-377-9993
404-778-3708
312-908-5250
617-632-5847
507-284-2511
402-559-5166
516-734-8959
646-608-4273
919-684-8111
614-293-3196
215-662-3933
615-524-4074
713-792-2860
908-208-4685
414-805-4600
+61882044018
+33240083271
+390226434797
+48124003200
+48223496334
+821071243234
+441132433144
+447728268414
+441752431043